Shattuck Labs, Inc. (STTK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on February 9, 2024, by Shattuck Labs, Inc., a Delaware corporation. The report details the entry into a Material Definitive Agreement with Ono Pharmaceutical Co., Ltd. ("Ono"), effective February 13, 2024. The agreement focuses on the research and preclinical development of bifunctional fusion proteins targeting specific therapeutic areas selected by Ono.
Key Financial Metrics and Agreement Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for the reporting period. Instead, it outlines the financial structure of the new collaboration:
- Upfront and Research Funding: Shattuck is entitled to receive up to $9 million, comprising an initial upfront payment and milestone payments tied to the Research Plan. Ono will also cover all costs and expenses incurred by Shattuck during the Research Plan.
- Option Milestones: If Ono exercises its exclusive option to license the Development Compounds, Shattuck could receive up to $217.5 million in licensing, clinical, regulatory, and commercial milestone payments.
- Royalties: Shattuck is entitled to tiered royalties on global net sales ranging from mid-single digits to low double digits, payable for a maximum of ten years after the first commercial sale in a specific country.
Material Changes and Strategic Developments
The primary material change is the execution of the Collaboration Agreement. Key strategic elements include:
- Scope: Collaboration on preclinical development of compounds directed toward a pair of targets from Shattuck's pipeline.
- Roles: Shattuck leads research activities under a Joint Research Committee; Ono holds an exclusive option to license, develop, manufacture, and commercialize resulting products worldwide.
- Exclusivity: Both parties are prohibited from commercializing products with the same mechanism of action as the Development Compounds during the agreement term.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement provides potential significant future revenue streams contingent on research milestones and the exercise of the option. Shattuck intends to file the full agreement as an exhibit to its Form 10-Q for the quarter ended March 31, 2024.
Risks and Termination:
- Termination Rights: Ono may terminate the agreement at any time with 90 days' written notice, requiring payment of Shattuck's costs up to the termination date. Either party may terminate for uncured material breach or insolvency.
- Contingency: Shattuck may terminate if Ono discontinues development efforts after the conditions to exercise the Option are met.
- Uncertainty: The $217.5 million in potential milestones and royalty income are not guaranteed and depend on future clinical, regulatory, and commercial successes.
Investor Verification Checklist
- Verify the exact amount of the initial upfront payment received versus the total $9 million potential research funding.
- Review the specific "Development Compounds" and targets selected by Ono to assess scientific viability.
- Monitor the timeline for the Research Plan and the 90-day window for Ono to exercise the option after the final report.
- Check the upcoming Form 10-Q for the full text of the Collaboration Agreement to review detailed milestone definitions and termination clauses.
- Assess Shattuck's current cash runway to determine if the upfront payment is critical for immediate operations.